# Bosentan

Drug · id `cardio:bosentan` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: TRACLEER

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Bosentan, sold as Tracleer, is an endothelin receptor antagonist. The US label lists treating pulmonary arterial hypertension (WHO Group 1): in adults, to improve exercise ability and to decrease clinical worsening, and, separately, in pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension. The label carries a boxed warning about two risks: the label says elevations of liver aminotransferases and liver failure have been reported, and that the medicine may cause fetal harm if used during pregnancy. The fetal risk concerns the unborn child and is recorded separately.

## Technical summary

RxNorm ingredient 75207 (RxNorm also holds 498193, bosentan monohydrate, which has no RxClass classes); UNII Q326023R30; MeSH D000077300 is Bosentan (identity only: the descriptor carries no scope note). RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, so the record is filed under the class page. The label read is the Actelion Pharmaceuticals US, Inc. label for Tracleer, applications NDA021290 (approved 2001-11-20 as a new molecular entity in Drugs@FDA) and NDA209279, effective 2025-11-17 in openFDA. The adult and pediatric statements, the liver warning (recipient not stated) and the fetal warning (recipient: fetal) sit in separate claims and contexts. This page records label indications, the boxed-warning wording named, the mechanism sentence and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: The developing fetus, for a person taking bosentan during pregnancy, as described in a US label boxed warning

Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Tracleer carries, within the same boxed warning, a statement that, based on animal data, the medicine may cause fetal harm if used during pregnancy.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Application number of the label read, NDA021290.
  2. Background: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Effective date of the label text read, 20251117.
  3. Supports: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Label passage quoted in the research quote table (Q-K29-TRA-LB-07).
  4. Supports: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], highlights text. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Label passage quoted in the research quote table (Q-K29-TRA-LB-09).

## Context: Patients taking bosentan, as described in the hepatotoxicity part of a US label boxed warning

Recipient: Recipient not specified; Population: Patients who take the medicine, as the label boxed warning describes the liver risk. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Tracleer carries a boxed warning titled risks of hepatotoxicity and embryo-fetal toxicity. For the liver, it says elevations of liver aminotransferases and liver failure have been reported with the medicine.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients who take the medicine, as the label boxed warning describes the liver risk. The passage read gives no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the passage read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the boxed-warning statement named above only. The warning also says the medicine is available only through a restricted program and gives monitoring instructions; those instructions are not repeated here. The embryo-fetal part of the warning is in a separate claim about the fetus. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Application number of the label read, NDA021290.
  2. Background: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Effective date of the label text read, 20251117.
  3. Supports: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Label passage quoted in the research quote table (Q-K29-TRA-LB-07).
  4. Supports: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], highlights text. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Label passage quoted in the research quote table (Q-K29-TRA-LB-08).

## Context: Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as described in the US label of Tracleer

Recipient: Child; Population: Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients aged 3 years and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of Tracleer separately lists treating pulmonary arterial hypertension in pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, to improve pulmonary vascular resistance.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Pediatric patients aged 3 years and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The adult use is in a separate claim. The label's own sentence that the improvement in pulmonary vascular resistance is expected to result in better exercise ability was not recorded.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Application number of the label read, NDA021290.
  2. Background: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Effective date of the label text read, 20251117.
  3. Supports: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Label passage quoted in the research quote table (Q-K29-TRA-LB-06).

## Context: Adults with pulmonary arterial hypertension, as described in the US label of Tracleer

Recipient: Adult; Population: Adults with pulmonary arterial hypertension (WHO Group 1), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)

### The US label of Tracleer (bosentan tablets and tablets for oral suspension, Actelion Pharmaceuticals US, Inc., applications NDA021290 and NDA209279; the version dated 2025-11-17 in openFDA) describes bosentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group 1) in adults to improve exercise ability and to decrease clinical worsening.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with pulmonary arterial hypertension (WHO Group 1), as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the label states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists a pediatric use, which sits in a separate claim.
- Last checked: 2026-11-18
- Sources:
  1. Background: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].openfda.application\_number\[0\]. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Application number of the label read, NDA021290.
  2. Background: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Effective date of the label text read, 20251117.
  3. Supports: openFDA drug label record for Tracleer (bosentan tablets and tablets for oral suspension), Actelion Pharmaceuticals US, Inc. label: indications, boxed warning and mechanism (Regulator, edition The openFDA drug label record for set id 749e42fb-2fe0-45dd-9268-b43bb3f4081c (manufacturer Actelion Pharmaceuticals US, Inc., application NDA021290 and NDA209279), returned on 2026-11-18. The label text is dated 2025-11-17 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22749e42fb-2fe0-45dd-9268-b43bb3f4081c%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-18T22:01:31Z. Source state: Current. Version fingerprint: fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4.
     How it applies: Label passage quoted in the research quote table (Q-K29-TRA-LB-04, Q-K29-TRA-LB-05).

## Connected pages

- Bosentan is an endothelin receptor antagonist (FDA established pharmacologic class in RxClass): Endothelin receptor antagonists (`cardio:endothelin-receptor-antagonists`)
- FDA label lists pulmonary arterial hypertension (WHO Group 1) in adults, to improve exercise ability and to decrease clinical worsening, as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-tracleer-label-indications` and its context]
- FDA label separately lists pulmonary arterial hypertension in pediatric patients aged 3 years and older with idiopathic or congenital disease as an indication: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-tracleer-label-paediatric` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 208635f46665896361bd27b1336fe1ba6f830a80f7697e65814d7a685e7960f2
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
